Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the potential of aducanumab and the amyloid theory in patients with Alzheimer disease.
Endovascular treatment may benefit patients with emergent large vessel occlusion and target mismatch profiles regardless of the time from onset.
The chief research officer and epilepsy specialist at Cleveland Clinic detailed her most recent findings on the cost-effectiveness of epilepsy surgery for drug-resistant temporal lobe epilepsy.
The presence of laryngeal movement disorders—identified in 93% of the MSA group—may serve as a diagnostic biomarker of MSA independent of phenotype, disease duration, or patient age.
Michael R. Sperling, MD, provides an overview of a case of a 16-year-old male diagnosed with idiopathic generalized epilepsy.